Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Recruiting · Phase 2 · NCT07170917
Conditions: Hidradenitis Suppurativa
At a glance
- Research payments reported, 2025
- $98,930
- U.S. investigators named
- 5
- Sites paid
- 4
- Planned or actual enrollment
- 208
About the trial
- Sponsor
- Sanofi
- Tested
- Brivekimig (drug), Placebo (drug)
- Dates
- Started 2025-11-06; completion 2029-11-23
- Results posted
- Not yet
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 164 weeks for participants transitioning into the long-term extension (LTE) period and will be up to approximately 60 weeks for participants not transitioning into the LTE period. The randomized treatment duration will be up to approximately 152 weeks
From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $98,930 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Navid Ezra, M.D. Dermatology · Thousand Oaks, CA
- Ira H. Thorla JR., M.D. Dermatology · Baton Rouge, LA
- Kathleen P. Gordon, DO Internal Medicine · Johnston, RI
- Brandon J. Coakley, MD Mohs Surgery · Myrtle Beach, SC
- Marc T. Mitton, D.O Dermatology · Washington Terrace, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Alliance for Multispecialty Research LLC $48,230
- Northridge Clinical Trials Llc $24,450
- Delricht LLC $16,000
- Clinical PArtners Llc $10,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.